PE & DVT treatment. Classification of Emboli - Fat and Marrow ◦Sequelae from any marrow/adipose injury ◦fat and cells are released into bloodstream ◦CPR,

Slides:



Advertisements
Similar presentations
Nursing Care & Interventions for Clients with Vascular Problems
Advertisements

DISEASES ANEMIA ANEURYSM ARTERIOSCLEROSIS ATHEROSCLEROSIS CONGESTIVE HEART FAILURE EMBOLUS HEMOPHILIA.
Acute venous or arterial thrombosis Acute venous or arterial thrombosis Is there an indication for thrombolysis? Baseline labs: CBC, PT, PTT, fibrinogen.
Controversies in the management of Pulmonary Embolism
Chapter Six Venous Disease Coalition Acute Management of VTE VTE Toolkit.
Venous Thromboembolism (VTE) Prophylaxis Policy Mary-Anne Davies Patient Safety Specialist Accreditation Coordinator.
Clinical Knowledge Summaries CKS Pulmonary embolism (PE)
WELCOME.
CHEST-2012: High Points and Pearls Alan Brush, MD, FACP Chief, Anticoagulation Management Service Harvard Vanguard Medical Associates.
DPT 732 SPRING 2009 S. SCHERER Deep Vein Thrombosis.
Venous thromboembolism: how long to treat?
Embolism.
+ Pulmonary Embolus By: Marissa Miuccio. + What is a Pulmonary Embolism Pulmonary Embolism, or PE, is a sudden blockage in a lung artery. The blockage.
LIFEBLOOD THE Thrombosis CHARITY Venous thromboembolism – Treatment and secondary prevention Ulcus cruris Chronic PE PE DVT Post-thrombotic syndrome Death.
Unprovoked DVT in a young patient
DVT & VARICOSE VEINS.
Pulmonary Embolism Jeannette Corona. Title: Alteplase Treatment of Acute Pulmonary Embolism in the Intensive Care Unit Authors: Pamela L. Smithburger,
Pulmonary Embolism. Definition: Sudden lodgment of a blood clot in a pulmonary artery with subsequent obstruction of blood supply to the lung parenchyma.
Thromboembolism IT training Presentation Midwifery update Marie Lewis.
NURS 1950 Pharmacology I 1.  Objective 1: identify general reasons anticoagulants are given 2.
Chapter 3 Disorders of Vascular Flow Yiran Ni M.D
Total Joint Replacement
Study Guide Guide for Patients Undergoing Anticoagulant Therapy.
Pleural diseases: Case Studies
Anemia Inadequate number of red blood cells, hemoglobin or both.
To Clot Or Not To Clot… Emergency Care for Coagulation Disorders/Conditions Rebecca Goldsmith Pediatric Thrombosis/Hemophilia Nurse McMaster Children’s.
Case Report Pneumology Dr. David Tran A&E, FVHospital Medical meeting September 28 th, 2011.
P ULMONARY E MBOLISM. W HAT IS A PULMONARY E MBOLISM ? A Pulmonary Embolism occurs when major blood vessels (arteries) in the lungs become blocked. Usually.
Moderate Pulmonary Embolism Treated with Thrombolysis (MOPETT) Trial Mohsen Sharifi, Curt Bay, Laura Skrocki, Farnoosh Rahimi, Mahshid Mehdipour A.T.Still.
Peripheral Vascular Disease Megan McClintock. Peripheral Artery Disease Definition Etiology/Pathophysiology Signs & symptoms Complications Diagnostic.
CARDIOVASCULAR MODULE: DEEP VENOUS THROMBOSIS THROMBOPHLEBITIS Adult Medical-Surgical Nursing.
VTE Venous ThromboEmbolism. VTE – aims of this module To define the terms associated with VTE and offer maximum care to treat patients. To define the.
PULMONARY EMBOLI Kenney Weinmeister M.D.. PULMONARY EMBOLI w Over 500,000 cases per year. w Results in 200,000 deaths. w Mortality without treatment is.
Thrombophilia. Definition –Tendency to develop clots due to predisposing factors that may be genetically determined.
Hemodynamics, Thromboembolism and Shock Review with Animations Nicole L. Draper, MD.
Presented by: Passant Mounir Nagy Under the supervision of: Prof. Dr/ Seham Hafez.
Deep vein thrombosis Pulmonary embolism Deep vein thrombosis Pulmonary embolism Venous Thromboembolism TreatmentTreatment …All the same?
Jomo Osborne Lung-2015 Baltimore, USA July , 2015.
Pulmonary Embolism Pulmonary embolism is blockage in one or more arteries in your lungs. Maggie Trainor.
Drugs Used to Treat Thromboembolic Disorders Chapter 27 Mosby items and derived items © 2010, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc.
DVT & PE: How early can I mobilize a patient ??
E MBOLISM An embolus is a detached intravascular solid, liquid, or gaseous mass that is carried by the blood to a site distant from its point of origin.
Drugs Susan Louw Haematology Registrar. 4 Questions to ask: Can I stop? (What is the risk of thrombosis?) Should I stop? (What is the risk of bleeding?)
ALTERATIONS IN THE NERVOUS SYSTEM
Agents Affecting Blood Clotting
Coagulation Modifier Agents Lilley Pharmacology Text: Chapter 26 Original Text modified by: Anita A. Kovalsky, R.N., M.N.Ed. Professor of Nursing Original.
DVT cases.  Heparin, low molecular weight heparin, or fondaparinux are usually continued for at least five days, along with another medication called.
PULMONARY EMBOLISM BY Dr. Hayam Hebah Associate professor of internal medicine AL-Maarefa College.
Cardiovascular Disorders Unit 7.8 Circulatory System.
Coagulation disorders in pregnancy. Hematological Changes During Pregnancy: 1-Expansion of plasma volume and hemodilution. 2-Hb level increases, but there.
DEEP VEIN THROMBOSIS BLOCK 2 Lecture Professor Nora Martin Vetto.
One of the main causes of DVT is inactivity! When a person is inactive, your blood normally collects in the lower part of your body. (in your legs) This.
Outpatient DVT assessment & treatment Daniel Gilada.
By : Saad Gharaibeh Anwar Al-Kassar Samah Telfah Abd-elsalam Sleman Venous Thrombo-embolism (VTE) 1.
Aim: How can we prevent malfunctions of the circulatory system?
The VERITY Steering Committee
Deep Vein Thrombosis & Pulmonary Embolism
Embolism: An embolus is a detached intravascular solid, liquid, or gaseous mass that is carried by the blood to a site distant from its point of origin.
EMBOLISM.
By: Dr. Nalaka Gunawansa
Clinical Knowledge Summaries CKS Pulmonary embolism (PE)
Pathology Department KSU, Riyadh 2015
Confirmed VTE Treatment Pathway
Circulatory disorders
ANTICOAGULANTS Dr. A. Shyam Sundar. M.Pharm., Ph.D,
Problem Solving in Medicine
Deep Vein Thrombosis By Jonah Paul Cox.
CIRCULATORY SYSTEM Characteristics and Treatment of Common Cardiac and Circulatory Disorders.
Pathology Department KSU, Riyadh 2015
Presentation transcript:

PE & DVT treatment

Classification of Emboli - Fat and Marrow ◦Sequelae from any marrow/adipose injury ◦fat and cells are released into bloodstream ◦CPR, long bone fractures, setting of soft tissue or burns.

Air ◦Clinical effect: >100 cc air ◦Air coalesce  frothy masses ◦Introduced via surgical procedures, e.g. Laparoscopic, obstetric, bypass ◦Decompression sickness: deep sea divers, underwater workers.

Amniotic Fluid ◦Amniotic fluid/fetal tissue in maternal circulation ◦Originates at tears of placental membranes or rupture of uterine veins. ◦5 th most common cause of maternal mortality

Tx of DVT Goals: ◦prevent clot propagation ◦Prevent pulmonary hypertension ◦recurrence of clot Tx: anticoagulant therapy + warfarin 6-12 weeks ◦Non-pharm measures: leg elevation, heat application, compression stockings ◦Can treat with outpatient based (except PE)

Tx of PE 1. oxygen 100% 2. morphine IV if pain/distressed 3. Massive PE: thrombolysis/surgery 4. IV  heparin as guided by APTT 5. Systolic BP ◦>90mmHg: warfarin  confirm Dx PE ◦<90mmHg:colloid infusion  noradrenaline  consider thrombolysis (if not step 3)

Anticoagulant Therapy Delay in Dx: treat presumptively Contraindications: intracranial bleeding, severe active bleeding, recent brain, eye, or spinal cord surgery, and malignant hypertension Heparin ◦Activates antithrombin to II, VII, IX, X, XI, XII Warfarin ◦Inhibits reductase to activate Vit K – cofactor of cascade

Unfractionated Heparin Pros ◦Cheaper ◦Use for patients with renal insufficiency/failure ◦Indicated for submassive/massive PE ADR: ◦Thrombocytopenia (transient 10-20%), major bleeding (2%) ◦Risk: >65yrs, recent surgery, liver disease

Low Molecular Weight Heparin LMWH (Fractionated Heparin) ◦more predictable anticoagulant effects ◦does not require blood monitoring ◦outpatient therapy ◦Longer half-life ◦Subcutaneous admin. ◦ADRs of UF less likely

Warfarin Therapy starts when acute anticoagulation is achieved starting Tx at 5 mg per day Titrating the dosage every 3-7 days to achieve an INR between 2.0 and 3.0 ◦E.g. Day 3 INR <3 10 mg/day or INR < mg/day

Thrombolytic Therapy Not used for DVTs Used when anticoagulant therapy fails Indicated for massive PE Include: streptokinase, tPA via IV

Surgical Therapy A transvenous catheter embolectomy or open surgical embolectomy Indications: ◦thrombolytic therapy fails ◦Contraindicated for thrombolytic therapy ◦Massive PE + refractory hypotension Vena cava filters for recurrent PEs ◦Combined with anticoagulation therapy

Management Prevent further thrombosis Heparin + warfarin for ≥5 days. ◦Stop heparin at INR>2. Warfarin therapy depends on underlying cause, vary from 3-6 months or indefinite. Warfarin is contraindicated in pregnant women, use LWMH instead.